Zacks Research Analysts Cut Earnings Estimates for Neogen

Neogen Co. (NASDAQ:NEOG) – Research analysts at Zacks Research lowered their Q2 2025 earnings per share (EPS) estimates for Neogen in a research note issued to investors on Thursday, January 2nd. Zacks Research analyst R. Department now expects that the company will earn $0.11 per share for the quarter, down from their prior forecast of $0.12. The consensus estimate for Neogen’s current full-year earnings is $0.50 per share. Zacks Research also issued estimates for Neogen’s FY2027 earnings at $0.72 EPS.

Neogen (NASDAQ:NEOG) last released its quarterly earnings data on Thursday, October 10th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $217.00 million during the quarter, compared to the consensus estimate of $215.05 million. Neogen had a positive return on equity of 2.80% and a negative net margin of 2.58%. The business’s revenue was down 5.2% on a year-over-year basis. During the same period last year, the company earned $0.11 EPS.

NEOG has been the topic of a number of other reports. StockNews.com upgraded Neogen to a “sell” rating in a research report on Monday, September 30th. Guggenheim assumed coverage on Neogen in a research report on Thursday, December 19th. They issued a “buy” rating and a $15.00 target price on the stock.

Neogen Stock Performance

NASDAQ NEOG opened at $12.25 on Monday. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of -111.36 and a beta of 1.21. The company has a quick ratio of 2.79, a current ratio of 4.41 and a debt-to-equity ratio of 0.28. The business has a 50-day moving average price of $13.65 and a 200-day moving average price of $15.19. Neogen has a twelve month low of $11.46 and a twelve month high of $19.88.

Institutional Investors Weigh In On Neogen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NEOG. Commonwealth Equity Services LLC raised its position in Neogen by 3.4% during the second quarter. Commonwealth Equity Services LLC now owns 36,630 shares of the company’s stock valued at $573,000 after purchasing an additional 1,190 shares during the period. Natixis Advisors LLC raised its position in Neogen by 12.6% during the second quarter. Natixis Advisors LLC now owns 71,313 shares of the company’s stock valued at $1,115,000 after purchasing an additional 7,954 shares during the period. Rhumbline Advisers raised its position in Neogen by 0.3% during the second quarter. Rhumbline Advisers now owns 715,254 shares of the company’s stock valued at $11,179,000 after purchasing an additional 1,860 shares during the period. TD Asset Management Inc raised its holdings in shares of Neogen by 14.1% in the second quarter. TD Asset Management Inc now owns 160,316 shares of the company’s stock worth $2,506,000 after buying an additional 19,800 shares during the period. Finally, Victory Capital Management Inc. raised its holdings in shares of Neogen by 26.5% in the second quarter. Victory Capital Management Inc. now owns 495,028 shares of the company’s stock worth $7,737,000 after buying an additional 103,815 shares during the period. 96.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO John Edward Adent acquired 14,500 shares of the firm’s stock in a transaction on Friday, October 11th. The shares were acquired at an average cost of $13.80 per share, for a total transaction of $200,100.00. Following the completion of the transaction, the chief executive officer now directly owns 216,477 shares in the company, valued at approximately $2,987,382.60. This trade represents a 7.18 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.13% of the stock is owned by company insiders.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.